KinDex was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease
KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction. TAS2Rs are found in multiple tissue types and regulate hormones that play a key role in chronic disease such as Polycystic Ovary Syndrome (PCOS), obesity, NASH and diabetes. Our lead candidate, KDT501, is an orally dosed, small molecule modulator of TAS2Rs that has been demonstrated safe and effective in Phase 1 and 2 clinical trials. Our next goal is to study the effects of KDT501 in patients with PCOS.
PCOS is a common endocrine disorder affecting between 5 and 10 % of women of reproductive age1. Many PCOS patients have a family history of diabetes or insulin resistance or a close relative who is similarly affected by androgen excess. Irregular ovulation in combination with excess androgens, excess hair growth (hirsutism), acne and obesity can all occur in women with PCOS. Women with PCOS are at greater risk for type 2 diabetes and cardiovascular disease and possibly hypertension and abnormal lipid levels.
The annual cost in 2005 in the USA for diagnosis and treatment of PCOS was $4.36 billion2.
